Navigation Links
Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
Date:9/11/2007

Deerfield, IL, September 11, 2007 Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke, or death among a diverse population of 16,390 patients with diabetes versus control therapy.

This new meta-analysis is consistent with the depth and breadth of ACTOS cardiovascular data: ACTOS studies, conducted over the past 10 years, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

Meta-analyses are pooled data across a number of studies. Although not definitive, they can offer insight into aspects of a compound or product that may not be readily available from individual studies. The overall effect calculated from a group of like or similar randomized trials can provide an estimate of the drugs overall effects in an expanded population.

This meta-analysis adds important information to the body of evidence regarding ACTOS and macrovascular ischemic events, and further documents the consistency of data from prospective studies, to meta-analysis, to observational studies.

Critical in this body of data is PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events), a trial of patients with type 2 diabetes who are at high risk for cardiovascular events. Results from this prospective, randomized, placebo-controlled outcomes trial - considered by scientists to be the most scientifically rigorous type of study - were reviewed by the FDA and added to the ACTOS label. These data show no increase in mortality or total macrovascular events with ACTOS. ACTOS is the only thiazolidinedione (TZD) with s
'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
646-935-3917
Ketchum
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
2. Substituting soymilk for lactose intolerant students n schools: a great option
3. ACTOS Linked to Several Cardiovascular Benefits
4. Lactose-Intolerant kids need to take dairy products to meet nutrient requirements
5. Actos Linked To Bone Fractures In Diabetic Women
6. Largest Ever Study of Genetics Behind Common Diseases Published
7. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
8. Findings on Dangerous Parasite, Toxoplasma Gondii Published
9. Siddha Medicine Texts to Be Published in English
10. Journal Recommends How To Improve The Performance Of Health Workers
11. Medical Journals should create awareness on Child survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... NE (PRWEB) , ... July 07, 2015 , ... ... center for MRI services, is debuting their brand new website. The website’s goal ... technology and a wider selection of patient tools, including requesting appointments online. , ...
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for ... of Massachusetts , and the Multicultural AIDS Coalition $3.78 million for a ... have sex with men (MSM) and transgender women, the groups at highest risk ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Quadrino Law Group ... Road, Suite 304, Melville, New York 11747. The new facility is a state ... and rail lines. , Richard Quadrino, the firm's CEO and founder, said, "We are ...
(Date:7/7/2015)... N.J. (PRWEB) , ... July ... ... CTLT), the leading global provider of advanced delivery technologies and development solutions ... signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody ...
(Date:7/7/2015)... ... July 07, 2015 , ... Summer is a great time ... so Amica Insurance is sharing some safety tips. , Jean Tapley, senior wellness coordinator ... Leisure activities/sports, , Start slowly. Going from no activity to ...
Breaking Medicine News(10 mins):Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2
... people don,t get enough rest , THURSDAY, June 11 (HealthDay ... can actually boost your odds for dying prematurely, while another ... getting the recommended eight hours of slumber. , All three ... Societies annual meeting, in Seattle. , The first study, from ...
... BOSTON, June 11 GlobalEquityReport.com is ... Investors who are interested in stocks on the move and in ... http://www.GlobalEquityReport.com , , Today,s ... Generex Biotechnology, Corp. (Nasdaq: GNBT ), Cell Therapeutics, Inc. ...
... Amy G. Hise, M.D., M.P.H., assistant professor at the Center ... of Medicine, is the first to discover how the body ... human fungal pathogen, Candida . As ... research may directly lead to the development of new drugs ...
... tons of food to Volunteer,s of America City Harvest. , ... Denver" food drive by arc Thrift Stores brought in fourteen ... Stores will deliver 112 tons of non-perishable food to Volunteers ... 2009 between 8:00am and noon. This enormous shipment will require ...
... and ring finger (CHFR) is a mitotic stress checkpoint ... of cancer. In gastric cancer, CHFR promoter hypermethylation has ... genetic instability is one of the hallmarks of human ... Oki from Kyushu University examined the methylation status of ...
... (those who have not given birth to children) are ... and rheumatoid arthritis (RA) an average of 5.2 years ... children), according to a new study presented today at ... Against Rheumatism in Copenhagen, Denmark. Previous studies have highlighted ...
Cached Medicine News:Health News:Lack of Good Sleep Might Be Deadly 2Health News:Lack of Good Sleep Might Be Deadly 3Health News:GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN 2Health News:Researchers at Case Western Reserve discover a new way the body fights fungal infection 2Health News:Coloradoan's Love Affair with Giving Grows! 2Health News:Diagnosis of arthritis 5 years earlier in childless women compared to those with children 2
(Date:7/7/2015)... and BANGALORE , July ... a global technology provider of innovative clinical trial data ... (Industry Standard Research Reports) recent publication named " EDC ... Performance (2015) ". ISR Reports is one of the ... industry, and this report evaluated 22 EDC and eCOA ...
(Date:7/7/2015)... --  InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... systems ("EPS"), today announced that its MGuard Prime ... ™ has received the Frost & Sullivan ...  Through active market research efforts, Frost & Sullivan,s ... successful introduction of new and innovative products, with ...
(Date:7/7/2015)...   Bionik Laboratories Corp. (OTCBB: BNKL), ... core focus in robotic exoskeleton technology for users ... today that it has completed an additional sale ... its common stock and warrants for aggregate gross ... placement transaction.  This equity financing is the sixth ...
Breaking Medicine Technology:Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 5Bionik Laboratories Completes US$13.1 Million Private Placement 2Bionik Laboratories Completes US$13.1 Million Private Placement 3
... WELLINGTON , Fla., May 10 Dr. ... children with newly diagnosed type 1 diabetes for Protege Encore, ... second of two Phase III studies testing the safety and ... known as Protege, has completed enrollment of more than 530 ...
... Ireland , May 10 Warner Chilcott plc ... of America Merrill Lynch Healthcare Conference on Tuesday, May 11, 2010 ... be Paul Herendeen , Executive Vice President and Chief Financial Officer. , ... Warner Chilcott ,s presentation will be ...
Cached Medicine Technology:Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
IOL choppers for positioning intraocular lenses. Blunt tip avoids damage to intraocular lenses. For .20mm diameter holes and larger....
...
...
...
Medicine Products: